Impact of Azole Antifungals on the Conversion Ratio of Immediate-release Tacrolimus to LCP-Tacrolimus Tablets in Non–kidney Solid Organ Transplant Recipients
Retrospective cohort study explores azole antifungals' effect on tacrolimus conversion in non-kidney transplant recipients, suggesting dosage adjustments may be needed.
Key Points
This study aims to determine the effect of azole antifungal use on the conversion ratio from immediate-release tacrolimus to LCP-Tacrolimus in non-kidney transplant recipients.
Single-center, retrospective cohort study from 2015 to 2022.
Included adult non-kidney transplant recipients converted from IR-Tac to LCPT.
Patients were grouped based on azole antifungal use to assess conversion ratios.
113 transplant recipients included, with 22 (19.5%) on azole antifungals.
Conversion ratios were significantly higher for patients on azoles at 7 days (P=0.031), 30 days (P=0.038), and 90 days (P=0.001).
Neurological adverse effects led to conversion in 55 patients; 79.3% reported improvement on LCPT.